[go: up one dir, main page]

AR111367A1 - N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso - Google Patents

N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso

Info

Publication number
AR111367A1
AR111367A1 ARP180100886A ARP180100886A AR111367A1 AR 111367 A1 AR111367 A1 AR 111367A1 AR P180100886 A ARP180100886 A AR P180100886A AR P180100886 A ARP180100886 A AR P180100886A AR 111367 A1 AR111367 A1 AR 111367A1
Authority
AR
Argentina
Prior art keywords
fluorine
substituted
alkyl
trisubstituted
phenyl
Prior art date
Application number
ARP180100886A
Other languages
English (en)
Inventor
Nagel Jens Dr
Drbner Karoline Dr
Mller Jrg Dr
Hauff Peter Dr
Jrien Hannah Dr
Mosig Johanna Dr
Bairlein Michaela Dr
Dietz Lisa Dr
Von Bhler Clemens Dr
- Dr Stellfeld Timo Jeremias
Frstner Chantal Dr
Meininghaus Mark Dr
Kast Raimund Dr
Beck Hartmut Dr
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of AR111367A1 publication Critical patent/AR111367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Compuestos de la fórmula (1), caracterizados porque Ar representa fenilo o piridilo, donde fenilo puede estar hasta tetrasustituido y piridilo hasta disustituido, en cada caso de manera igual o diferente, con flúor, cloro, con alquilo C₁₋₄ hasta trisustituido con flúor, con cicloalquilo C₃₋₄ hasta tetrasustituido con flúor, con alcoxi C₁₋₂ hasta trisustituido con flúor, o con alquilsulfanilo C₁₋₂ hasta trisustituido con flúor, o donde dos sustituyentes del grupo fenilo o piridilo, si están unidos a átomos anulares adyacentes, dado el caso están unidos de manera tal que juntos forman un grupo metilendioxi- o etilendioxi, o donde fenilo puede estar sustituido hasta cinco veces con flúor; Y representa una unión o un grupo de la fórmula: #¹-X-(CR¹⁰AR¹⁰B)ₖ-#², donde #¹ representa el punto de unión con el átomo de carbono; #² representa el punto de unión con el grupo carboxi; X representa una unión, -CH₂-, -O-, -S(=O)ₘ- o -N(R¹¹)-, en la que m significa 0, 1 ó 2, y R¹¹ significa hidrógeno o metilo; R¹⁰A y R¹⁰B independientemente entre sí representan hidrógeno, flúor o metilo, o R¹⁰A y R¹⁰B forman junto con el átomo de carbono al que están unidos, un grupo ciclopropilo; k representa 1, 2, 3 ó 4; R¹ representa halógeno, alquilo C₁₋₄ sustituido hasta cinco veces con flúor, metoxi hasta trisustituido con flúor, (trifluorometil)sulfanilo, pentafluorosulfanilo, trimetilsililo, etinilo, ciclopropilo, o ciclobutilo, donde ciclopropilo y ciclobutilo pueden estar sustituidos hasta cuatro veces con flúor; R², R³ y R⁴ independientemente entre sí representan hidrógeno, halógeno o metilo hasta trisustituido con flúor; R⁵ representa halógeno, alquilo C₁₋₄ sustituido hasta cinco veces con flúor, metoxi hasta trisustituido con flúor, hidroxi, metilsulfanilo, (trifluorometil)sulfanilo, ciano, etenilo, ciclopropilo o ciclobutilo, donde ciclopropilo y ciclobutilo pueden estar sustituidos hasta cuatro veces con flúor; R⁶ representa -NR¹²R¹³, donde R¹² significa hidrógeno o alquilo C₁₋₃, y R¹³ significa alquilo C₁₋₄ o cicloalquilo C₃₋₇, donde cicloalquilo C₃₋₇ puede estar sustituido hasta cuatro veces con flúor y alquilo C₁₋₄ puede estar sustituido hasta cinco veces con flúor o estar monosustituido con cicloalquilo C₃₋₆, metoxi, trifluorometoxi o fenilo, donde fenilo puede estar hasta trisustituido con flúor, o representa un heterociclo bicíclico de 6 a 10 miembros, monocíclico de 4 a 8 miembros, saturado o parcialmente insaturado, unido por medio de un átomo de nitrógeno, que puede contener un heteroátomo adicional, igual o diferente de la serie N, O, S, SO o SO₂ como miembro anular, donde el heterociclo bicíclico de 6 a 10 miembros, monocíclico de 4 a 8 miembros puede estar sustituido en cada caso con 1 a 3 sustituyentes seleccionados independientemente entre sí del grupo alquilo C₁₋₄, hidroxi, oxo, alcoxi C₁₋₃, difluorometoxi, trifluorometoxi, ciano, amino, monometilamino, dimetilamino, aminocarbonilo, monometilaminocarbonilo, dimetilaminocarbonilo y además puede estar sustituido hasta cuatro veces con flúor, donde alquilo C₁₋₄ puede estar sustituido hasta cinco veces con flúor o estar monosustituido con hidroxi o metoxi; R⁷A y R⁷B independientemente entre sí representan hidrógeno o metilo, o R⁷A y R⁷B forman junto con el átomo de carbono al que están unidos, un grupo ciclopropilo; R⁸ representa hidrógeno, flúor, metilo, trifluorometilo, etilo o hidroxi; R⁹ representa hidrógeno o metilo; así como sus N-óxidos, sales, solvatos, sales de los N-óxidos y solvatos de los N-óxidos y sales.
ARP180100886A 2017-04-10 2018-04-10 N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso AR111367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17165674 2017-04-10

Publications (1)

Publication Number Publication Date
AR111367A1 true AR111367A1 (es) 2019-07-03

Family

ID=58530431

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100886A AR111367A1 (es) 2017-04-10 2018-04-10 N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso

Country Status (19)

Country Link
US (1) US11149018B2 (es)
EP (1) EP3609870A1 (es)
JP (1) JP7125420B2 (es)
KR (1) KR20190138825A (es)
CN (1) CN110709384A (es)
AR (1) AR111367A1 (es)
AU (1) AU2018251087B2 (es)
BR (1) BR112019021130A2 (es)
CA (1) CA3059954A1 (es)
CO (1) CO2019011227A2 (es)
EA (1) EA201992389A1 (es)
IL (1) IL269836B (es)
MX (1) MX2019012152A (es)
PE (1) PE20191738A1 (es)
PH (1) PH12019502315A1 (es)
TW (1) TWI770157B (es)
UA (1) UA125660C2 (es)
UY (1) UY37671A (es)
WO (1) WO2018189012A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
EP4259156A4 (en) * 2020-12-11 2025-02-12 Elise A. Olsen COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531458T2 (de) * 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US20090069301A1 (en) 2005-03-03 2009-03-12 Sirtris Pharmaceuticals, Inc. Acridine and Quinoline Derivatives as Sirtuin Modulators
KR101762574B1 (ko) 2009-03-31 2017-07-28 가부시키가이샤 레나사이언스 플라즈미노겐 액티베이터 인히비터-1 저해제
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2635280A4 (en) 2010-11-05 2014-05-28 Univ Minnesota CYTOSINDEAMINASE MODULATORS TO IMPROVE DNA TRANSFECTION
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
JP6120951B2 (ja) 2012-05-03 2017-04-26 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 新規ｅｐ２受容体作動薬
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
WO2014117090A1 (en) 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
DK3083554T3 (da) 2013-12-17 2019-05-13 Lilly Co Eli Dimethylbenzoesyreforbindelser
WO2016004035A1 (en) 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases
CN107074773A (zh) * 2014-09-09 2017-08-18 拜耳制药股份公司 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途
EP3206689B1 (en) 2014-10-14 2021-12-08 La Jolla Institute of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
WO2016146602A1 (de) 2015-03-18 2016-09-22 Bayer Pharma Aktiengesellschaft Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf

Also Published As

Publication number Publication date
UA125660C2 (uk) 2022-05-11
US11149018B2 (en) 2021-10-19
US20200157073A1 (en) 2020-05-21
TWI770157B (zh) 2022-07-11
IL269836B (en) 2022-04-01
CO2019011227A2 (es) 2019-10-21
KR20190138825A (ko) 2019-12-16
TW201900616A (zh) 2019-01-01
AU2018251087A1 (en) 2019-10-31
MX2019012152A (es) 2019-11-21
UY37671A (es) 2018-11-30
EA201992389A1 (ru) 2020-04-03
IL269836A (en) 2019-11-28
CA3059954A1 (en) 2018-10-18
JP2020513026A (ja) 2020-04-30
CN110709384A (zh) 2020-01-17
EP3609870A1 (de) 2020-02-19
PH12019502315A1 (en) 2020-07-06
JP7125420B2 (ja) 2022-08-24
AU2018251087B2 (en) 2021-11-18
BR112019021130A2 (pt) 2020-09-01
PE20191738A1 (es) 2019-12-12
WO2018189012A1 (de) 2018-10-18

Similar Documents

Publication Publication Date Title
AR111367A1 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
AR099023A1 (es) Pirazolil-heteroarilamidas como agentes plaguicidas
UY37103A (es) Compuestos de piperidina sustituido y su uso
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR095464A1 (es) Compuestos de heteroarilo y usos de los mismos
EA201891615A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
AR097866A1 (es) Derivados de 4-azaindol
MX387359B (es) Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
AR109706A1 (es) INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g
BR112017003356A2 (pt) composição estabilizante térmica e composição de resina sintética compreendendo a mesma
AR100327A1 (es) Inhibidores de quinasa relacionados con tropomiosina
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
CL2019000462A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional solicitud 201603258)
AR095040A1 (es) Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina
AR100448A1 (es) 5-(hetero)aril-piridazinonas y su uso como herbicida
EA202190285A1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
AR096490A1 (es) Moduladores del receptor cxcr7
AR087089A1 (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico
BR112018000065A2 (pt) compostos de aril sulfonamida como inibidores de anidrase carbônica e seu uso terapêutico
AR096984A1 (es) Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona
AR107570A1 (es) Compuestos químicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal